The Prognostic Importance of Polypharmacy in Older Adults Treated for Acute Myelogenous Leukemia (AML)

Overview

Journal Leuk Res

Date 2014 Aug 17

PMID 25127690

Citations 28

Authors

Kathleen Elliot

Janet A Tooze

Rachel Geller

Bayard L Powell

Timothy S Pardee

Ellen Ritchie

LeAnne Kennedy

Kathryn E Callahan

Heidi D Klepin

Affiliations

Soon will be listed here.

Abstract

We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML.

Citing Articles

Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers.

Wondm S, Moges T, Dagnew S, Dagnew F, Zeleke T, Abebe R J Pharm Policy Pract. 2024; 17(1):2397797.

PMID: 39359864 PMC: 11445903. DOI: 10.1080/20523211.2024.2397797.

Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer.

Ma Z, Xu M, Fu M, Huang T, Shi L, Zhang Y BMC Geriatr. 2024; 24(1):550.

PMID: 38918727 PMC: 11197362. DOI: 10.1186/s12877-024-05138-3.

Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol.

Ramsdale E, Mohamed M, Holmes H, Zubkoff L, Bauer J, Norton S J Geriatr Oncol. 2024; 15(2):101687.

PMID: 38302299 PMC: 10923001. DOI: 10.1016/j.jgo.2023.101687.

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML.

Min G, Cho B, Kwag D, Park S, Park S, Yoon J Front Oncol. 2023; 13:1281782.

PMID: 38023260 PMC: 10661959. DOI: 10.3389/fonc.2023.1281782.

Considerations and analysis of the implementation of oncogeriatrics in Chile and its importance: Review of current literature.

Honorato M, Calderon O, Rojas V, Fasce G, Bartolotti C, Caglevic C Front Aging. 2023; 4:1141792.

PMID: 37033403 PMC: 10077059. DOI: 10.3389/fragi.2023.1141792.

References

Sasaki T, Fujita K, Sunakawa Y, Ishida H, Yamashita K, Miwa K . Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. Int J Clin Oncol. 2012; 18(4):735-42. DOI: 10.1007/s10147-012-0425-5. View

Ko Y, Tan S, Chan A, Wong Y, Yong W, Ng R . Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther. 2012; 34(8):1696-704. DOI: 10.1016/j.clinthera.2012.06.025. View

Sherman A, Motyckova G, Fega K, DeAngelo D, Abel G, Steensma D . Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013; 37(9):998-1003. PMC: 3735611. DOI: 10.1016/j.leukres.2013.05.013. View

Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C . The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98(5):1312-20. DOI: 10.1182/blood.v98.5.1312. View

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

Kantarjian H, Ravandi F, OBrien S, Cortes J, Faderl S, Garcia-Manero G . Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010; 116(22):4422-9. PMC: 4081299. DOI: 10.1182/blood-2010-03-276485. View

Kantarjian H, OBrien S, Cortes J, Giles F, Faderl S, Jabbour E . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106(5):1090-8. DOI: 10.1002/cncr.21723. View

Extermann M, Boler I, Reich R, Lyman G, Brown R, DeFelice J . Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2011; 118(13):3377-86. DOI: 10.1002/cncr.26646. View

Hamaker M, Mitrovic M, Stauder R . The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014; 93(6):1031-40. DOI: 10.1007/s00277-013-2001-0. View

10.

Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland M, Schaich M . Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010; 376(9757):2000-8. DOI: 10.1016/S0140-6736(10)62105-8. View

11.

Charlson M, Szatrowski T, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47(11):1245-51. DOI: 10.1016/0895-4356(94)90129-5. View

12.

Marcum Z, Amuan M, Hanlon J, Aspinall S, Handler S, Ruby C . Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2011; 60(1):34-41. PMC: 3258324. DOI: 10.1111/j.1532-5415.2011.03772.x. View

13.

Turner J, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S . Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014; 22(7):1727-34. DOI: 10.1007/s00520-014-2171-x. View

14.

Etienne A, Esterni B, Charbonnier A, Mozziconacci M, Arnoulet C, Coso D . Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007; 109(7):1376-83. DOI: 10.1002/cncr.22537. View

15.

Riechelmann R, Moreira F, Smaletz O, Saad E . Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005; 56(3):286-90. DOI: 10.1007/s00280-004-0998-4. View

16.

Prithviraj G, Koroukian S, Margevicius S, Berger N, Bagai R, Owusu C . Patient Characteristics Associated with Polypharmacy and Inappropriate Prescribing of Medications among Older Adults with Cancer. J Geriatr Oncol. 2012; 3(3):228-237. PMC: 3375830. DOI: 10.1016/j.jgo.2012.02.005. View

17.

Puts M, Monette J, Girre V, Costa-Lima B, Wolfson C, Batist G . Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010; 27(7):559-72. DOI: 10.2165/11537310-000000000-00000. View

18.

Wheatley K, Brookes C, Howman A, Goldstone A, Milligan D, Prentice A . Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009; 145(5):598-605. DOI: 10.1111/j.1365-2141.2009.07663.x. View

19.

Hamaker M, Seynaeve C, Wymenga A, van Tinteren H, Nortier J, Maartense E . Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. Breast. 2013; 23(1):81-7. DOI: 10.1016/j.breast.2013.11.004. View

20.

Sganga F, Landi F, Ruggiero C, Corsonello A, Vetrano D, Lattanzio F . Polypharmacy and health outcomes among older adults discharged from hospital: results from the CRIME study. Geriatr Gerontol Int. 2014; 15(2):141-6. DOI: 10.1111/ggi.12241. View